
NASDAQHealthcareBiotechnology
最新資料
US$554.73
−US$4.37 · -0.78%
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
前收盤價
US$554.73
−US$4.37 · -0.78%
盤中時間採用ET。市場資料可能有所延遲。
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
日內區間
目前US$554.73
52週區間
目前US$554.73
盤中時間採用ET。市場資料可能有所延遲。
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
日內區間
目前US$554.73
52週區間
目前US$554.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 31.83億 USD | 28.77億 USD | 23.28億 USD | 19.36億 USD | 16.86億 USD |
| 銷貨成本 | 3.84億 USD | 3.1億 USD | 2.58億 USD | 1.47億 USD | 1.23億 USD |
| 毛利 | 27.98億 USD | 25.68億 USD | 20.7億 USD | 17.9億 USD | 15.63億 USD |
| 研究與開發 | 5.5億 USD | 4.81億 USD | 4.08億 USD | 3.23億 USD | 5.4億 USD |
| 銷售、一般及管理費用 | 7.31億 USD | 6.39億 USD | 4.77億 USD | 4.87億 USD | 4.67億 USD |
| 營業費用 | 12.81億 USD | 11.91億 USD | 8.85億 USD | 8.1億 USD | 10.07億 USD |
| 利息收入 | 1.92億 USD | 1.99億 USD | 1.63億 USD | 4520萬 USD | 1670萬 USD |
| 利息支出 | 1950萬 USD | 4290萬 USD | 5930萬 USD | 3240萬 USD | 1860萬 USD |
| 折舊和攤銷 | 8560萬 USD | 7250萬 USD | 5320萬 USD | 5130萬 USD | 4990萬 USD |
| 營業利益 | 15.17億 USD | 13.77億 USD | 11.85億 USD | 9.8億 USD | 5.56億 USD |
| 淨利 | 13.35億 USD | 11.95億 USD | 9.85億 USD | 7.27億 USD | 4.76億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Core S&P Mid-Cap ETFIJH8.57億0.75%1150.6億 USD0.05%US$68.60-2.68%
Vanguard Morningstar Total Stock Market ETFVTI6.44億0.04%6893億 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB5.76億0.32%787億 USD0.03%US$270.68-2.56%
Vanguard Extended Market ETFVXF2.91億0.31%302億 USD0.05%US$211.44-3.21%
Vanguard Morningstar Small-Cap Value ETFVBR1.87億0.28%371億 USD0.05%US$231.38-2.02%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.8億0.73%245.19億 USD0.23%US$626.03-2.64%
iShares Biotechnology ETFIBB1.78億1.70%105.27億 USD0.44%US$199.54-2.05%
Invesco S&P MidCap Quality ETFXMHQ1.68億3.03%54.04億 USD0.30%US$111.72-2.21%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap Value ETFVBR
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares Biotechnology ETFIBB
Invesco S&P MidCap Quality ETFXMHQAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。